Why the study?
Does melperone antagonize experimental arrhythmias in animal models compared to standard antiarrhythmics?
Does melperone antagonize experimental arrhythmias in animal models compared to standard antiarrhythmics?
Melperone demonstrates anti-arrhythmic properties in experimental animal models, suggesting potential as a type III anti-arrhythmic drug.
Answers are grounded in this paper and cite their sources.
Melperone's antiarrhythmic effects in animals do not support clinical use; leaves open its potential as a type III agent in humans.
The neuroleptic butyrophenone, melperone, has been compared with antiarrhythmics, neuroleptics, alpha-blockers and beta-blockers in various experimental arrhythmias. Melperone 0.01--1 mg/kg intravenously antagonized ouabain-induced arrhythmias in conscious rabbits to the same degree as propranolol 2 mg/kg and quinidine 10 mg/kg intravenously probably mainly via s CNS depressive effect. It was found to be considerably weaker than propranolol 2 mg/kg, when anaesthetized guinea pigs were used. Melperone 0.1--10 mg/kg was inactive against aconitine-induced arrhythmias. Melperone 1--5 mg/kg antagonized adrenaline-induced arrhythmias in halothane-sensitized guinea pigs like phentolamine 1--5 mg/kg intravenously and was more potent than chlorpromazine, propranolol and quinidine. This study and an electrophysiological study suggest that melperone might be a type III anti-arrhythmic drug, which at the same time depresses CNS and reduces afterload.
No takes yet. Share an insight, caveat, or question.
Erling N. Petersen (1978) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: